

Letter to the Editor

Progestogen in menopausal hormone therapy and breast cancer risk

Jin-Sung Yuk, MD, PhD

Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University,

Seoul, Korea

Running title:

Received: 2024.03.12.

Accepted: 2024.04.03.

Corresponding author: Jin-Sung Yuk, MD, PhD

Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University,

1342 Dongil-ro, Nowon-gu, Seoul 01757, Korea

E-mail: dryjs01@gmail.com

<https://orcid.org/0000-0002-5478-634X>

Menopausal hormone therapy (MHT) is widely used to treat menopausal symptoms, but concerns about breast cancer risk remain a major barrier, particularly following the Women's Health Initiative (WHI) study involving conjugated equine estrogen (CEE)/medroxyprogesterone acetate (MPA) [1]. Consequently, in Korea, there has been a notable decline in the prescription frequency of CEE+MPA, owing to its association with breast cancer [2]. However, compared to CEE+MPA, estradiol hemihydrate (EH)/drospirenone (DRSP) (Angeliq[®], COMPANY, CITY, STATE, COUNTRY), EH/norethisterone acetate (NETA) (Clian[®], COMPANY, CITY, STATE, COUNTRY), EH/dydrogesterone (DYD) (Femoston conti[®], COMPANY, CITY, STATE, COUNTRY; Femoston 2/10[®], COMPANY, CITY, STATE, COUNTRY; and Femoston 1/10[®], COMPANY), and estradiol valerate (EV)/cyproterone acetate (CPA) (Climen[®]) have been prescribed more frequently in South Korea [2]. This might be due to the lack of large-scale studies pertaining to the risk of breast cancer associated with these agents.

However, numerous studies have demonstrated that the risk of breast cancer associated with MHT is primarily influenced by progestogens rather than by estrogen. The findings from the WHI study revealed that women with a hysterectomy who used only CEE did not exhibit an increased risk of breast cancer, as opposed to those who were prescribed CEE in combination with MPA [1]. Furthermore, the E3N study showed that the type of progestin used in MHT can affect the breast cancer risk [3]. Micronized progesterone (MP) and DYD were not associated with increased breast cancer risk, whereas other progestogens were [3]. The Health Insurance Database in South Korea-1 study found that estrogen-progestogen therapy (EPT) provided as a single-pill [e.g., EH/DRSP,

EH/NETA, and EH/DYD) delivery system by pharmaceutical companies, was associated with increased breast cancer risk [4]. However, no increased risk was observed for estrogen only, transdermal estrogen, tibolone, or EPT provided as a double-pill (e.g., EH+MP) by a physician.

Therefore, it is necessary to study the risk of breast cancer associated with the various EPTs prescribed in South Korea. In a recent study conducted in Korea which used Health Insurance Review and Assessment Service data, EH/DRSP (Angeliq®) (hazard ratio [HR], 1.511; 95% confidence interval [CI], 1.38-1.655), EH/NETA (Clia®) (HR, 1.664; 95% CI, 1.343-2.063), EH/DYD (Femoston conti®, Femoston 2/10®, and Femoston 1/10®) (HR, 1.367; 95% CI, 1.115-1.676), and EV/CPA (Climen®) (HR, 1.741; 95% CI, 1.544-1.964] were associated with a higher risk of breast cancer [2]. EV/MPA and EV/NETA also had increased HRs, although these were not statistically significant owing to the small number of prescriptions. However, MP was not associated with breast cancer risk.

The overall dose or potency of progesterone may be more important than its components in terms of influencing the risk factors of breast cancer, for several reasons: first, when physicians can adjust the progesterone dosage, such as with MP (100 or 200 mg) (Utrogestan®, COMPANY, CITY, STATE, COUNTRY), the risk of breast cancer did not increase significantly [4]. Second, EH/DYD although associated with an increased risk of breast cancer, tended to be at a lower risk than other progestogens. EH/DYD (Femoston conti®, Femoston 2/10®, and Femoston 1/10®) was associated with a mix of doses (DYD 5 or 10 mg) and methods of use (continuous or sequential method), resulting in a lower total amount of progestogen prescribed per month. Therefore, further research is warranted regarding the relation between breast cancer risk and EPT formulations containing low

doses of progestogens.

In conclusion, when prescribing single-pill EPT, clinicians should thoroughly inform patients about the potentially increased risk of breast cancer by employing an approach similar to that used for CEE+MPA in the past. However, the absolute increase in risk is relatively low (approximately 1 breast cancer case per 1,000 women per year) [2,4]. This emphasizes the importance of individualized discussions and treatment plans that consider the medical history, risk factors, and preferences of each patient. For patients seeking MHT with a lower breast cancer risk than single-pill EPT, options such as tibolone, tissue-selective estrogen complex, transdermal estrogen, or estrogen alone (for women who have undergone hysterectomy) can be considered as first-line options.

Conflict of interest

Author declares no competing interests.

Ethical approval

Patient consent

Funding information

None.

REFERENCES

1. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. *JAMA* 2013;310:1353-68.
2. Yuk JS. Relationship between menopausal hormone therapy and breast cancer: a nationwide population-based cohort study. *Int J Gynaecol Obstet* 2024 Mar 12 [Epub]. <https://doi.org/10.1002/ijgo.15461>.
3. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat* 2008;107:103-11.
4. Yuk JS, Kim T, Cho H, Gwak G. Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea-based cohort study. *Eur J Endocrinol* 2024;190:1-11.